Skip to main content
Terug
RDY logo

Dr. Reddy's Laboratories Limited

Datakwaliteit: 100%
RDY
NYSE Healthcare Drug Manufacturers - Specialty & Generic
€ 13,45
▼ € 0,24 (-1,75%)
Marktkapitalisatie: 11,20B
Dagbereik
€ 13,40 € 13,67
52-Weeksbereik
€ 12,26 € 16,17
Volume
1.639.098
50D / 200D Gem.
€ 13,97 / € 14,25
Vorige Slotkoers
€ 13,69

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,2 0,4
P/B 0,0 2,9
ROE % 18,4 3,7
Net Margin % 17,4 3,9
Rev Growth 5Y % 236,0 10,0
D/E 0,1 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2028 € 68,20
€ 64,21 – € 77,06
 400 B 1
FY2027 € 55,78
€ 52,94 – € 62,40
 360 B 2
FY2026 € 61,47
€ 59,55 – € 64,35
 350 B 2

Belangrijkste Punten

Revenue grew 235,95% annually over 5 years — strong growth
ROE of 18,42% — decent returns on equity
Net margin of 17,37% shows strong profitability
Debt/Equity of 0,14 — conservative balance sheet
Generating 12,03B in free cash flow
P/E of 0,20 — trading at a low valuation

Groei

Revenue Growth (5Y)
235,95%
Revenue (1Y)16,61%
Earnings (1Y)1,54%
FCF Growth (3Y)-45,17%

Kwaliteit

Return on Equity
18,42%
ROIC14,17%
Net Margin17,37%
Op. Margin22,07%

Veiligheid

Debt / Equity
0,14
Current Ratio1,92
Interest Coverage25,40

Waardering

P/E Ratio
0,20
P/B Ratio0,03
EV/EBITDA0,60
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16,61% Revenue Growth (3Y) 15,06%
Earnings Growth (1Y) 1,54% Earnings Growth (3Y) 12,01%
Revenue Growth (5Y) 235,95% Earnings Growth (5Y) 295,03%
Profitability
Revenue (TTM) 325,54B Net Income (TTM) 56,54B
ROE 18,42% ROA 11,47%
Gross Margin 58,50% Operating Margin 22,07%
Net Margin 17,37% Free Cash Flow (TTM) 12,03B
ROIC 14,17% FCF Growth (3Y) -45,17%
Safety
Debt / Equity 0,14 Current Ratio 1,92
Interest Coverage 25,40 Dividend Yield 0,01%
Valuation
P/E Ratio 0,20 P/B Ratio 0,03
P/S Ratio 0,03 PEG Ratio 10,58
EV/EBITDA 0,60 Dividend Yield 0,01%
Market Cap 11,20B Enterprise Value 43,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 325,54B 279,16B 245,88B 214,39B 2,56B
Net Income 56,54B 55,68B 45,07B 23,57B 232,21M
EPS (Diluted) 67,77 66,80 54,17 28,34 20,73
Gross Profit 190,43B 163,61B 139,34B 113,84B 1,30B
Operating Income 71,84B 67,73B 57,14B 29,48B 431,44M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 492,99B 387,52B 321,85B 292,83B 3,63B
Total Liabilities 155,82B 106,97B 90,86B 102,30B 1,26B
Shareholders' Equity 333,39B 280,55B 230,99B 190,53B 2,37B
Total Debt 46,77B 20,02B 13,47B 33,85B 414,53M
Cash & Equivalents 14,65B 7,11B 5,78B 14,85B 202,82M
Current Assets 250,11B 248,05B 204,25B 181,86B 2,03B
Current Liabilities 130,39B 96,04B 85,85B 94,02B 1,14B

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#229 of 825
54
Growth Price/Sales Ratio Focus (Ken Fisher)
#435 of 618
22
Custom Contrarian Investing (David Dreman)
#595 of 670
6
Value Defensive Investing (Benjamin Graham)
#436 of 710
22

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026